The target of our investigation is the bromodomain-containing protein 4 (BRD4). Bromodomains are a major and rapidly evolving focus for the pharmaceutical industry with inhibitors targeting them having shown promising pre-clinical efficacy in pathologies ranging from cancer to inflammation. BRD4, in particular, has recently become something of a benchmark system for free energy calculations , including for those based on MMPBSA .